Abbott gets expanded approval for HPV assay
November 2025—FDA approves Abbott’s Alinity m HR HPV assay for self-collected vaginal samples in clinical settings.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
CytoCell KMT2A FISH probe kit granted de novo classification
November 2025—FDA granted de novo classification for OGT’s CytoCell KMT2A Breakapart FISH Probe Kit PDx as a companion diagnostic for Syndax’s menin inhibitor, Revuforj.
Tosoh gets clearance for next-gen GR01 HbA1c analyzer
November 2025—Tosoh Bioscience received FDA clearance for its HLC 723-GR01 analyzer, which uses proprietary technology to deliver A1c results in 50 seconds and detect common hemoglobin variants.
Molecular Designs submits respiratory panel for 510(k) clearance
November 2025—Molecular Designs submitted a 510(k) premarket notification to the FDA for its SimplicityDx Respiratory panel, designed to detect SARS-CoV-2, influenza A, influenza B, and RSV.
Guardant, PathGroup partner to expand access to Shield test
November 2025—Guardant Health and PathGroup are partnering to expand access to Guardant’s FDA-approved Shield blood test for colorectal cancer screening.
Data presented at ACEP25 show the utility of MeMed BV
November 2025—Presentations at the American College of Emergency Physicians Scientific Assembly 2025 highlighted MeMed BV’s effectiveness in distinguishing between bacterial and viral infections.
Quickvue Influenza + SARS test available for professional use
November 2025—QuidelOrtho’s Quickvue Influenza + SARS test, a CLIA-waived immunoassay, is now available for professional use.
Quest launches advanced PGx test service
November 2025—Quest Diagnostics launched a pharmacogenomic laboratory test service to help providers understand a patient’s genetic response to drug therapies.
QuidelOrtho launches certified analyzer program
October 2025—QuidelOrtho Corp. has launched a certified analyzer program designed to expand access to high-quality diagnostic testing in rural and community hospitals across the United States. The program is tailored for clinics, physician office labs, and small hospitals with fewer than 100 beds. Each analyzer in the program undergoes a robust, multipoint certification process at QuidelOrtho’s Rochester, NY, facility. It includes more than 140 system checks, functional adjustments, hardware cleaning or replacement, and extensive performance testing. The program features certified Vitros XT 7600 and 5600 integrated systems and the Vitros 3600 immunodiagnostic system. A 12-month warranty on service and support is included.
StatLab launches PiSmart S1 slide printer
October 2025—StatLab Medical Products has launched the PiSmart S1 single hopper slide printer. The PiSmart S1 features an intuitive touchscreen interface and a compact footprint that supports on-demand printing. Four years of service is included with the use of StatLab-validated slides, which will soon be manufactured at the company’s Arlington, Tex., facility. This integrated approach—pairing printers with precision-manufactured, validated KT premium slides—creates a complete solution built for accuracy and reliability, according to a press release from StatLab.